What is Tremelimumab?

Category: Prescription Drugs


Tremelimumab (formerly ticilimumab, CP-675,206) is an antibody that is in clinical trials for several different types of cancer.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 0

Commonly reported side effects and conditions associated with Tremelimumab

Side effect Patients
Fatigue 1

Why patients stopped taking Tremelimumab

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped taking Tremelimumab


Stopped taking Tremelimumab

Duration Patients
1 - 6 months 1
Last updated:
There are no evaluations for Tremelimumab.